Mindpeak, European leader in Artificial Intelligence in Pathology, today announced the launch of a new CE marked deep learning algorithm for breast cancer diagnosis. "Mindpeak Breast Ki-67 HS" is the first AI software worldwide which directly proposes automatically recognized and analyzed hotspots to the pathologist upon first opening the images.
"Mindpeak Breast Ki-67 HS is a milestone in the development of tools to assist pathologists in the diagnosis of breast tissue. When pathologists open a new case (= patient) for the first time, our AI has already pre-processed and analyzed it so that the results only need to be reviewed. This saves a large amount of time and increases reproducibility," explains Felix Faber, CEO and founder of Mindpeak. At the same time, this product is the first in a series of new products that the company will be launching in the coming weeks.
Breast cancer is among the most common cancer types worldwide and is the most common cancer in women. The detection and quantification of immunohistochemically stained breast tumor cells is a challenging task for a pathologist, as the diagnosis has a direct impact on the treatment decision for the patient. The task itself - without AI support - is tedious and error-prone.
Founded by Faber and Dr Lang, the company has been developing image recognition software for pathologists using artificial intelligence since 2018. In doing so, Mindpeak has developed the first AI solution for digital pathology to make it into routine clinical practice in both Europe and the US. In partnership with international laboratories and leading pathology system providers, Mindpeak continues to expand its product range and develop it into an indispensable part of the digitised pathology workflow. This has made Mindpeak the most integrated company in this field globally.
"Mindpeak Breast Ki-67 HS is a milestone in the development of tools to assist pathologists in the diagnosis of breast tissue. When pathologists open a new case (= patient) for the first time, our AI has already pre-processed and analyzed it so that the results only need to be reviewed. This saves a large amount of time and increases reproducibility," explains Felix Faber, CEO and founder of Mindpeak. At the same time, this product is the first in a series of new products that the company will be launching in the coming weeks.
Breast cancer is among the most common cancer types worldwide and is the most common cancer in women. The detection and quantification of immunohistochemically stained breast tumor cells is a challenging task for a pathologist, as the diagnosis has a direct impact on the treatment decision for the patient. The task itself - without AI support - is tedious and error-prone.
Founded by Faber and Dr Lang, the company has been developing image recognition software for pathologists using artificial intelligence since 2018. In doing so, Mindpeak has developed the first AI solution for digital pathology to make it into routine clinical practice in both Europe and the US. In partnership with international laboratories and leading pathology system providers, Mindpeak continues to expand its product range and develop it into an indispensable part of the digitised pathology workflow. This has made Mindpeak the most integrated company in this field globally.
